Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Subscribe To Our Newsletter & Stay Updated
